logo
Plus   Neg
Share
Email

Clearside Biomedical Inc. (CLSD) Has Soared To A New High On Study Results

Clearside Biomedical Inc. (CLSD) announced Monday morning that its Phase 3 study of suprachoroidal CLS-TA, in patients with macular edema associated with non-infectious uveitis, met its primary endpoint and all of its key secondary endpoints.

Clearside Biomedical has gapped open dramatically higher this morning and is now up 4.07 at $11.89 on the highest volume of the year. The stock has soared to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT